Physician profile
David Bettis
NPI 1053425603
$1,596.29
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,128 · 2020: $422 · 2021: $23.35 · 2022: $23.00.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $727.70 | 2019-2022 | |
| Eisai INC. | $193.36 | 2019-2020 | |
| Ptc Therapeutics, INC. | $114.90 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $101.07 | 2019 | |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $100.00 | 2019 | |
| Sunovion Pharmaceuticals INC. | $82.30 | 2019-2020 | |
| Greenwich Biosciences, INC. | $70.67 | 2019 | |
| Ucb, INC. | $59.53 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $36.34 | 2019 | |
| Novartis Pharmaceuticals Corporation | $34.30 | 2019-2020 | |
| Aquestive Therapeutics, INC. | $33.39 | 2019 | |
| Neurelis, INC. | $31.76 | 2020 | |
| Zogenix INC. | $10.97 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bettis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.